Evolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer Sells 12,888 Shares

Evolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the transaction, the director now owns 32,183 shares in the company, valued at $418,057.17. The trade was a 28.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Evolus Trading Up 1.9 %

Shares of EOLS opened at $13.20 on Friday. The business’s 50-day moving average price is $13.10 and its 200 day moving average price is $14.00. The stock has a market capitalization of $839.35 million, a P/E ratio of -14.51 and a beta of 1.28. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Analyst Ratings Changes

EOLS has been the subject of a number of recent analyst reports. Barclays raised their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV purchased a new position in Evolus during the 4th quarter valued at about $49,000. IFP Advisors Inc lifted its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Evolus in the 3rd quarter valued at $132,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the 4th quarter valued at $106,000. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the 4th quarter valued at $115,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.